SDC1 and plasma cell myeloma: Given its modified expression and pivotal function in promoting cancer advancement, SDC1 becomes an appealing prospect for cancer treatment, with various therapeutic approaches devised to address SDC1 in human cancers, such as BT062-DM4 [59], VIS832 [60], OC-46F2 [61] for Multiple myeloma, and Synstatin for breast cancer [62] and hepatocellular carcinoma [63].